Hovione India

Office

Deliver Global Solutions with Local Execution.

Recognizing the importance of Indian Pharma market and its growing global presence including US, Hovione has decided to open office in India in 2011 and established fully functional office in Mumbai in April 2013.

 

This was a significant initiative in line with Company’s commitment to serve Pharmaceutical Customers well by understanding their needs and provide them proficient support to bring new and off-patent drugs to market. Today, Hovione India office is networking with several leading pharma companies and supporting their generic drug development projects for India, US and other regulated markets. 

 

Goal of Hovione India

  • Deliver Global Solutions with Local Execution
  • Facilitate smooth interaction between Hovione and Pharmaceutical Companies
  • Focused attention to support new projects and product development
  • Strengthen relationship with Indian Pharmaceutical Companies

Hovione's APIs offer impeccable chemical purity and unique product performance.

You might be interested in:

Minocycline

 

Minocycline Hydrochloride

Minocycline base

Doxycycline

 

Doxycycline monohydrate

Doxycycline hyclate

Ivermectin

 Ivermectin

 

Download our Integrated Product List

 

 

Knowledge Center
ARTICLE

Gaining Experience in Continuous Manufacturing

Experts at Hovione describe progress being made in understanding how to optimize continuous processes for oral solid-dosage drug products.
Source: PharmTech
ARTICLE

A multicentre, randomized, double‐masked, parallel group, vehicle‐controlled phase IIb study

to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea
Source: British Journal of Dermatology
POSTER

Improving Efficiency of Taste Making through Spray Congealing

Source: AAPS

 

 

For inquiries about Hovione India, kindly fill the form below.

News

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025
Office
Address

Hovione Holding Limited
C/o WeWork, 2nd floor,
Oberoi Commerz - II,  1,
Off Western Express Highway,
Oberoi Garden City, Goregaon East, Mumbai, Maharashtra 400063
India
Tel.: +919 004 261 523

FDA logo | Hovione
infarmed logo | Hovione
Hovione MACAU - ISO14001 and ISO45001
HKQAA Certified Company | Hovione

Other Locations

Hovione Hong Kong

Office
Address

Hovione Holding Asia Limited
Aubin House, 11th Floor
171-172 Gloucester Road
Wanchai
Hong Kong SAR
Tel.: +852 2891 1836
Fax: +852 2891 0943 

View all details